Art Hewig

Art Hewig serves as the Vice President of Pivotal & Commercial Biologics Technical Development at Gilead Sciences since April 2021, leading a team of scientists and engineers in managing Gilead's biologics portfolio from late-stage development to commercialization. Previously, Art held various leadership roles at Amgen from January 2002 to March 2021, culminating in the role of Executive Director of Pivotal Drug Substance Process Development, overseeing significant teams and initiatives in drug substance processes. Art’s academic background includes a PhD in Chemical Engineering from Carnegie Mellon University and a combined BS and MS in Chemical Engineering from Rensselaer Polytechnic Institute.